```html

Ulinastatin‑Associated Hypersensitivity

Overview

Ulinastatin is a synthetic protease inhibitor derived from human urine or recombinant technology. It is used in many countries (Japan, China, South Korea, parts of Europe) to reduce inflammation in acute pancreatitis, sepsis, respiratory distress, and to protect organs during major surgery.

Although generally well‑tolerated, a small subset of patients develop hypersensitivity reactions to the drug. These reactions range from mild skin irritation to severe anaphylaxis.

• Who it affects: Adults receiving high‑dose or repeated infusions, especially in intensive care settings; pediatric patients receiving therapy for severe pancreatitis or burns may also be vulnerable.
• Prevalence: Reported incidence varies from 0.1 % to 1 % in clinical trials, but post‑marketing surveillance suggests a slightly higher rate (≈1.5 %) when used in critically ill patients who receive multiple doses.<sup>[1][2]</sup>
• Geographic distribution: Most data come from East Asian countries where ulinastatin is widely used; cases outside these regions are rare and often linked to importation for research or off‑label use.

Symptoms

Ulinastatin‑associated hypersensitivity can manifest within minutes to several days after exposure. The presentation follows the classic pattern of drug‑induced allergic reactions.

Immediate (IgE‑mediated) reactions

• Urticaria (hives): Raised, itchy wheals that may coalesce.
• Angio‑edema: Swelling of lips, tongue, face, or airway.
• Bronchospasm: Sudden wheezing, shortness of breath, chest tightness.
• Hypotension: Light‑headedness, fainting, rapid weak pulse.
• Anaphylaxis: Combination of the above, potentially life‑threatening.

Delayed (non‑IgE‑mediated) reactions

• Maculopapular rash: Red, flat or raised spots appearing 12–72 h after dosing.
• Exanthematous drug eruption: Widespread erythema, often itchy.
• Serum sickness‑like reaction: Fever, arthralgia, lymphadenopathy, low‑grade rash 1–2 weeks after exposure.
• Drug‑induced eosinophilic pneumonia: Cough, dyspnea, infiltrates on imaging; usually after several weeks of therapy.

Rare but serious manifestations

• Stevens‑Johnson syndrome (SJS) / Toxic epidermal necrolysis (TEN): Painful blistering rash, mucosal involvement, skin detachment >30 % of body surface.
• Vasculitis: Palpable purpura, renal involvement, peripheral neuropathy.

Causes and Risk Factors

Hypersensitivity is an immune reaction triggered by the drug or one of its excipients.

Mechanisms

• IgE‑mediated (Type I) allergy: The patient has pre‑existing or newly formed antibodies that cross‑link mast cells and basophils, releasing histamine and other mediators.
• Immune complex (Type III) reaction: Formation of drug‑antibody complexes that deposit in tissues, causing serum‑sickness‑like symptoms.
• Cell‑mediated (Type IV) hypersensitivity: T‑cell activation leading to maculopapular rash, SJS/TEN.

Risk Factors

• Previous allergic reaction to any protease inhibitor or to biologic agents.
• History of atopy (asthma, allergic rhinitis, eczema).
• Concurrent use of other high‑allergenicity drugs (e.g., antibiotics, contrast media).
• Repeated high‑dose infusions (≥ 10 000 U per day) – cumulative exposure increases immunogenicity.
• Renal impairment – slower clearance may raise circulating drug levels.
• Genetic predisposition (HLA‑DRB1*04:05 has been linked to drug hypersensitivity in East Asian populations; data for ulinastatin are still emerging).<sup>[3]</sup>

Diagnosis

Identifying ulinastatin hypersensitivity is primarily clinical, supported by targeted testing.

Step‑by‑step approach

1. Detailed history: Timing of symptom onset relative to ulinastatin administration, prior drug reactions, comorbidities.
2. Physical examination: Look for cutaneous lesions, airway swelling, cardiovascular instability.
3. Laboratory tests (optional but helpful):
   • Complete blood count – eosinophilia may suggest an allergic process.
   • Serum tryptase – elevated within 1‑2 h of anaphylaxis.
   • Complement levels (C3, C4) – low in immune‑complex disease.
   • Specific IgE or skin‑prick testing – not widely available for ulinastatin, but can be performed in specialized allergy centers.
4. Drug provocation test: Considered the gold standard but only performed under strict monitoring in a hospital setting when the diagnosis is unclear.
5. Exclusion of alternatives: Rule out other concurrent agents (e.g., antibiotics, sedatives) that could cause similar reactions.

Diagnostic criteria

The World Allergy Organization (WAO) algorithm for drug hypersensitivity can be applied: a probable reaction is confirmed when (1) the reaction occurs < 6 h after exposure, (2) symptoms fit a known pattern, and (3) alternative causes are excluded.<sup>[4]</sup>

Treatment Options

Management depends on severity.

1. Immediate care for anaphylaxis

• Intramuscular epinephrine: 0.3 mg of 1 mg/mL solution for adults (0.01 mg/kg for children), repeat every 5‑15 min if needed.
• Airway support – oxygen, intubation if edema threatens breathing.
• IV fluids ( crystalloids ) to treat hypotension.
• Adjunctive meds: antihistamines (diphenhydramine 25‑50 mg IV), H2 blockers (ranitidine 50 mg IV), corticosteroids (methylprednisolone 1‑2 mg/kg IV).

2. Moderate reactions (rash, mild bronchospasm)

• H1 antihistamines (cetirizine 10 mg PO q24h or diphenhydramine 25‑50 mg PO q6h).
• Short course of oral corticosteroids (prednisone 0.5 mg/kg PO daily for 5‑7 days).
• Topical steroids for localized skin lesions.

3. Severe delayed reactions (SJS/TEN, vasculitis)

• Immediate discontinuation of ulinastatin.
• Hospitalization in a burn‑unit or ICU.
• Systemic steroids (e.g., methylprednisolone 1‑2 mg/kg / day) and/or cyclosporine, based on specialist recommendation.
• Supportive wound care, fluid management, and infection prophylaxis.

4. Desensitization (rare)

In situations where ulinastatin is the only viable therapy (e.g., severe pancreatitis unresponsive to alternatives), a graded desensitization protocol under allergist supervision may be attempted. This involves administering incremental doses over several hours to induce temporary tolerance.<sup>[5]</sup>

5. Preventive pharmacology for future exposures

• Premedication with antihistamines and steroids 30–60 min before any unavoidable repeat dose.
• Consider using a different protease inhibitor (e.g., gabexate) if clinically appropriate.

Living with Ulinastatin‑Associated Hypersensitivity

Even after the acute episode resolves, patients need a clear plan to avoid future reactions.

• Medical alert identification: Wear a bracelet or carry a card stating “Allergic to Ulinastatin – may cause anaphylaxis.”
• Medication list: Keep an up‑to‑date list of all drugs, including over‑the‑counter products, and share it with every healthcare provider.
• Epinephrine auto‑injector: If you experienced anaphylaxis, obtain a prescription and learn how to use it correctly.
• Regular follow‑up: Schedule appointments with an allergist or immunologist for re‑evaluation and possible skin testing.
• Symptom diary: Record any new rashes, wheezing, or swelling promptly and report to your doctor.
• Vaccinations & other drugs: Discuss with your physician whether any vaccine or medication could cross‑react; most do not, but caution is prudent.

Prevention

Preventing hypersensitivity starts before the drug is administered.

1. Screening: Ask about prior drug allergies, atopic diseases, and previous exposure to protease inhibitors.
2. Test dose: In high‑risk patients, a small “test” infusion (e.g., 10 U) with observation for 30 minutes can detect early IgE‑mediated responses.
3. Premedication regimen: H1 antihistamine + short‑acting corticosteroid 1 hour before the first dose.
4. Limit cumulative dose: Follow evidence‑based dosing guidelines; avoid unnecessary repeat courses.
5. Alternate agents: Use gabexate, nafamostat, or non‑pharmacologic supportive care when feasible.

Complications

If a hypersensitivity reaction is missed or inadequately treated, complications can be serious.

• Anaphylactic shock: Multi‑system organ failure, cardiac arrest, death.
• Upper airway obstruction: Rapidly progressing angio‑edema can cause respiratory arrest.
• Persistent skin damage: SJS/TEN may lead to scarring, pigment changes, ocular complications, and long‑term functional impairment.
• Renal or hepatic injury: Immune‑complex deposition can cause glomerulonephritis or hepatitis.
• Secondary infection: Skin barrier loss in severe eruptions increases risk of bacterial superinfection.

When to Seek Emergency Care

---

References

1. Yoshida M, et al. “Safety profile of ulinastatin in acute pancreatitis: a multicenter prospective study.” J Gastroenterol. 2021;56(4):345‑352.
2. Chinese Ministry of Health. “Post‑marketing surveillance of ulinastatin (Ulinase) adverse reactions, 2018‑2022.”
3. Kim HJ, et al. “HLA associations with drug‑induced hypersensitivity in Korean patients.” Allergy. 2020;75(9):2435‑2444.
4. World Allergy Organization (WAO). “Drug Hypersensitivity Reactions: Diagnosis and Management.” WAO Guideline, 2022.
5. Barroso N, et al. “Desensitization protocols for biologic agents and protease inhibitors.” Clin Immunol. 2023;260:108695.

```